Skip to main content
Midas Edge

Entrada Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

TRDA$5.25+11.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)

Common Stock · Additional Paid‑in Capital · Accumulated Other Comprehensive Income (Loss) · Accumulated Deficit · Total Stockholders’ Equity
Shares · Amount
Balances at December 31, 202333,437,296$3$437,132$195$(194,970)$242,360
Issuance of common stock upon exercise of stock options377,669—2,782——2,782
Vesting of early exercised options13,069—51——51
Vesting of restricted stock units333,537—————
Purchase of common stock under the employee stock purchase plan45,964—574——574
Issuance of common stock and pre-funded warrants in registered direct offering, net of issuance costs of $3923,367,003199,60799,608
Stock‑based compensation——17,915——17,915
Other comprehensive loss———(238)—(238)
Net income————65,62665,626
Balances at December 31, 202437,574,538$4$558,061$(43)$(129,344)$428,678
Issuance of common stock upon exercise of stock options62,170$—$425$—$—$425
Vesting of early exercised options1,676$—$14$—$—$14
Vesting of restricted stock units571,581$—$—$—$—$—
Purchase of common stock under the employee stock purchase plan74,256$—$462$—$—$462
Stock‑based compensation—$—$19,609$—$—$19,609
Other comprehensive income—$—$—$695$—$695
Net loss—$—$—$—$(143,750)$(143,750)
Balances at December 31, 202538,284,221$4$578,571$652$(273,094)$306,133
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.